Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 5/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 5/20 | 1.00 |
| ▸ | ALOX5 | P09917 | 4/20 | 1.00 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.51 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.49 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | JUN | P05412 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10534390 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2ALOX5CYP11B1CYP11B2 | |
| SCHEMBL9596224 | 0.80 | PTGS1 (0.67) | PTGS1PTGS2ALOX5GABBR2GABBR1 | |
| SCHEMBL1821479 | 0.79 | PTGS1 (0.74) | PTGS1PTGS2ALOX5GABBR2GABBR1 | |
| SCHEMBL1821480 | 0.79 | PTGS1 (0.74) | PTGS1PTGS2ALOX5GABBR2GABBR1 | |
| SCHEMBL30505301 | 0.79 | ALOX5 (1.00) | PTGS1PTGS2ALOX5CYP11B1CYP11B2 | |
| SCHEMBL15391493 | 0.79 | ALOX5 (1.00) | PTGS1PTGS2ALOX5CYP11B1CYP11B2 | |
| SCHEMBL13554395 | 0.79 | ALOX5 (1.00) | PTGS1PTGS2ALOX5CYP11B1CYP11B2 | |
| SCHEMBL31049963 | 0.76 | ALOX5 (0.67) | PTGS1PTGS2ALOX5CYP11B1CYP11B2 | |
| SCHEMBL9302806 | 0.76 | ALOX5 (0.61) | PTGS1PTGS2ALOX5CYP11B1CYP11B2 | |
| SCHEMBL9301520 | 0.76 | ALOX5 (0.61) | PTGS1PTGS2ALOX5CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130005718-A1 | COMPOSITIONS AND METHODS OF TREATING CHRONIC PAIN BY ADMINISTERING PROPOFOL DERIVATIVES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2013-01-03 | — | — | US | disclosed |
| US-20130005718-A1 | COMPOSITIONS AND METHODS OF TREATING CHRONIC PAIN BY ADMINISTERING PROPOFOL DERIVATIVES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2013-01-03 | — | — | US | disclosed |
| WO-2011019747-A1 | COMPOSITIONS AND METHODS OF TREATING CHRONIC PAIN BY ADMINISTERING PROPOFOL DERIVATIVES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2011-02-17 | — | — | WO | disclosed |
| US-4812460-A | ANTIINFLAMMATORY, ARTHRITIS TREATMENT | BOEHRINGER INGELHEIM PHARMACEUTICAL, INC. (US) | 1989-03-14 | — | — | US | disclosed |
| US-4743606-A | 3-[2-(3',5'-di-t-butyl-4'-hydroxyphenyl)ethenyl]pyridine having anti-inflammatory and anti-arthritic properties | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1988-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005718-A1 | COMPOSITIONS AND METHODS OF TREATING CHRONIC PAIN BY ADMINISTERING PROPOFOL DERIVATIVES | HCN3, HCN1, HCN2 | PTGS1 227/4885PTGS2 228/4885ALOX5 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.